gastro-congress-2016_scientifictracks-abstracts

6 / 24

Volume 6, Issue 7(Suppl) J Gastrointest Dig Syst 2016
ISSN: 2161-069X JGDS, an open access journal
Page 28
Notes:
Gastro Congress 2016
October 24-25, 2016
conferenceseries.com
October 24-25, 2016 Valencia, Spain
9th Euro Global
Gastroenterology Conference
BRCA associated pancreatic cancer & other DNA repair deficiencies
Golan Talia
Chaim Sheba Medical Center, Israel
Pancreatic ductal adenocarcinoma (PDAC) continues to pose a challenge globally and is expected to represent the second
most common cause of cancer deaths in the next two decades. Familial clustering is found in about 10-15% of PDAC cases
(FPC) with an apparent autosomal dominant pattern of genetic transmission, suggestive of an inherited cancer syndrome. An
estimated 5% of FPC cases have DNA repair pathway aberrations. BRCA1 and BRCA2 deficient tumors, particularly in BRCA1/
BRCA2 germline mutation carriers, have a distinct clinical outcome and responsiveness to cisplatin-based therapy. PARPi may
offer therapeutic promise in these cases and a phase III clinical trial is currently underway. Another familial subset resembles
the BRCA- mutant clinical phenotype (displaying sensitivity to cisplatin therapy and improved prognosis) and maybe referred
to as having DNA repair deficiencies (DDR), although their underlying genetic mutation is undefined. Recent whole genome
sequencing studies have indicated that a subset of PDAC cases with genomic instability is enriched with BRCA1, BRCA2 or
PALB2 mutations and a signature of DNA damage repair deficiency. These subtype of patients who displayed remarkable
clinical response to DNA damaging agents thus suggesting the potential therapeutic effects of PARPi, extend beyond germline
BRCA 1/2 mutation carriers. PALB2, Rad51, ATM, RPA1, FANCM, REV1L, XRCC and HUWE1 GAs lead to DNA repair
defects and may represent potential targets for PARPi. Therefore, it is critical that we identify novel functional and cost-effective
tools to identify high-risk DDR cases without the necessarily interrogating each of these genetic aberrations individually. Our
group is studying this specific subgroup with clinical and translational studies.
Biography
Golan Talia is a Clinician-Scientist currently conducting translational laboratory research while also serving as the Medical Director in Chaim Sheba Medical Center.
Her clinical interest is in patients with pancreatic cancer. She is developing an innovative model based on primary tumor cells obtained from patients’ ascites. Her
career goals include expertise in clinical medicine, translational laboratory research and drug development.
Golan Talia, J Gastrointest Dig Syst 2016, 6:7(Suppl)